Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOV140101 in Advanced Solid Tumors
NCT03317743Phase 1Completed
- Sponsor
- Idience
- Start
- Aug 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venadaparib in solid tumor (advanced stage), sponsored by Idience. Primary endpoint: Dose Limiting Toxicities at 21 days. Started Aug 2017; status: completed.
02
Drugs
venadaparib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03317743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03317743.